Get the app
US › Healthcare

Sutro Biopharma (STRO)

US · Healthcare · Biotechnology

$10.94-4.54%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$9.8M
Revenue YoY
-84.6%
Net profit
$-38.5M
EPS
$-2.33
EPS estimate
$-2.04
Net margin
-391.6%

EPS came in at -2.33 against a street estimate of -2.04 — a miss of 14.2%.

Key statistics

Market cap
$190.0M
Forward P/E
10.0
P/B
2.11
Book value
$-6.23
EPS (TTM)
$-18.02
52-week high
$43.85
52-week low
$7.15
50-day MA
$18.48
200-day MA
$23.11
Beta
1.50

Analyst view

Analysts rate Sutro Biopharma a strong buy (13 buy, 0 hold, 1 sell out of 14) with an average price target of $47.23.

Shareholding

Insiders
2.26%
Institutions
98.91%

Largest institutional holders

FundStake
Perceptive Advisors LLC7.87%
Bvf Inc7.55%
Affinity Asset Advisors, LLC7.07%
BlackRock Inc6.77%
Samsara BioCapital, LLC6.41%
Kynam Capital Management, LP5.26%
Orbimed Advisors LLC4.49%
Balyasny Asset Management LLC4.29%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sutro Biopharma — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.